Tyler Patchen

ProMIS Neu­ro­sciences, a biotech fo­cused on de­vel­op­ing treat­ments for neu­rode­gen­er­a­tive dis­eases, closed a pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, that brought in $20.4 mil­lion.

Bio­con Gener­ics, a sub­sidiary of In­dia-based man­u­fac­tur­er Bio­con, has ac­quired an oral med­i­cine pro­duc­tion fa­cil­i­ty in Cran­bury, NJ, from gener­ic man­u­fac­tur­er Ey­wa Phar­ma for $7.7

Vaxart an­nounced on Wednes­day that a Phase II study of its oral norovirus vac­cine achieved the pri­ma­ry end­point of re­duc­ing the rate of in­fec­tion. The

Pfiz­er and Val­ne­va are tout­ing pos­i­tive re­sults in a Phase II tri­al for their Ly­me dis­ease vac­cine can­di­date when it was ad­min­is­tered as a boost­er.

Ko­re­an biosim­i­lar mak­er Cell­tri­on will be con­struct­ing a new man­u­fac­tur­ing fa­cil­i­ty in South Ko­rea. A re­port from Ko­rea Bio­med­ical Re­view on Tues­day said that Cell­tri­on

The Delaware Court of Chancery on Tues­day ruled in fa­vor of Ab­b­Vie, like­ly set­ting up the drug­mak­er to re­ceive most of the dam­ages it was

Mer­sana Ther­a­peu­tics said Wednes­day that pres­i­dent and CEO An­na Pro­topa­pas is re­tir­ing Sept. 10, and board mem­ber Mar­tin Hu­ber will take over her role. Pro­topa­pas,

CSL Vi­for will lay off 85 em­ploy­ees in the Bay Area fol­low­ing a strate­gic re­view con­duct­ed by CSL Behring, the par­ent com­pa­ny. The cuts are

The FDA on Tues­day ten­ta­tive­ly ap­proved a pe­di­atric ver­sion of an HIV-1 treat­ment fol­low­ing a suc­cess­ful pub­lic-pri­vate part­ner­ship be­tween the Clin­ton Health Ac­cess Ini­tia­tive, Uni­taid,

Ole­ma On­col­o­gy, the Bay Area biotech run by for­mer As­traZeneca ex­ec­u­tive Sean Bo­hen, raised $130 mil­lion from a pri­vate place­ment and a cred­it fa­cil­i­ty of